CALT Calliditas Therapeutics AB

Biotech Analyst Ratings

Latest News

1. 17 May 2022 First patient randomized in Phase 2 trial in head and neck cancer

   STOCKHOLM, May 17, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been randomized in the company's proof-of-concept Phase 2 study in patients with squamous cell carcinoma of the head and neck (SCCHN) with the NOX 1 and 4 inhibitor, setanaxib.

   The trial is a randomized, placebo-controlled, double-blind, proof-of-concept Phase 2 study. It will investigate the effect of setanaxib 800 mg twice daily in conjunction with pembrolizumab 200mg IV, administered every 3 weeks (the standard treatment regimen for this immunotherapy), in approximately 50 patients with moderate or high CAF-density tumours. A tumour biopsy will be taken prior to randomization…

   View Full Article
2. 14 May 2022 Calliditas Therapeutics Launches an Online Patient Platform

   STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX))) ("Calliditas") today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
   

   IgANConnect.com provides individuals who have just been diagnosed with IgA nephropathy, those who have been living with the disease for many years, and caregivers the tools to help understand and manage IgA nephropathy.

   The complimentary IgAN Connect Facebook page provides an environment where individuals living with the disease are encouraged to explore educational and motivational resources alongside other members of the community.

   "As a rare…

   View Full Article
3. 10 May 2022 Calliditas Therapeutics to participate in upcoming investor conferences

   STOCKHOLM, May 10, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX))) ("Calliditas") today announced that its management team will participate in the following upcoming investor conferences and events:          

   • The 8^th Annual LSX World Congress on May 10-11, 2022 in London, United Kingdom          

   • The ABGSC Life Science Summit on May 18-19, 2022, in Stockholm, Sweden.           

   • H.C. Wainwright Hybrid Global Investment Conference on May 23-26, 2022.           

   • Jefferies Healthcare Conference on June 8-10, 2022 in New York City, USA.          

   • Citi European Healthcare Conference on June 14-16, 2022 in London, United Kingdom

   At the LSX World Congress, Calliditas Chief Executive Officer Renée Aguiar-Lucander…

   View Full Article
4. 29 April 2022 Number of shares and votes in Calliditas Therapeutics

   STOCKHOLM, April 29, 2022 /PRNewswire/ -- During April, Calliditas Therapeutics AB (publ) has allotted 830,586 common shares within the company's warrant program issued in 2018. Thus, as of April 29, 2022, the number of shares and votes in the company amounts to 53,172,170.

   For further information, please contact:

   Mikael Widell, Investor relations

   Tel.: +46 703 11 99 60, email: [email protected]

   The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 10:00 a.m. CEST on April 29, 2022.

   About Calliditas

   Calliditas Therapeutics…

   View Full Article
5. 27 April 2022 Calliditas Therapeutics' 2021 Annual Report Published

   STOCKHOLM, April 27, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX))) today announces that the Annual Report for 2021 now is available at the company's website: www.calliditas.com.

   This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 18:00 CET on April 27, 2022.

   For further information, please contact:

   Marie Galay, IR Manager, Calliditas

   Tel.: +44 79 55 12 98 45, email: [email protected]

   About Calliditas

   Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan…

   View Full Article